Bayer cowboys up with PanTera, a supplier of starting material for next-gen radiopharmaceuticals

14 Feb 2024
www.fiercepharma.com
Acquisition
Bayer has struck a deal with PanTera of Belgium, which supplies actinium-225, a key building block material in the creation of the next generation of radiopharmaceuticals.
Bayer the biopharma industry flocks to antibody-drug conjugates because of their ability to act as guided biological missiles to eliminate cancer cells, some companies are embracing another solution that can precisely target cancer—radiopharmaceuticals.
Bayer is upping its ante in the space, signing on with PanTera, a new manufacturer of actinium-225 (Ac-225), a rare, alpha-emitting isotopecanceracts as starting material for a new generation of radiopharmaceuticals.cancer
Bayerthe agreement, PanTera will supply Ac-225 to Bayer for clinical trial needs startactinium-225 (Ac-225)f of 2024. It is the first deal with a major drugmaker for PanTera, a joint venture established two years ago by particle accelerator technology specialist IBA and the Belgium government’s nuclear research center SCK CEN.
While radiopharma trailblazer Novartis has had panBayeric cancer drug Lutathera on the market since 2018, with its follow-on Pluvicto arriving in 2022, those were developed using the beta-emitting isotope lutetium-177.IBA
“Radiopharmaceuticals that exiNovartis for therpancreatic cancerly basLutatheraetium-177 and a few other isotopes. Lutetium-1Pluvictoe big boom right now,” PanTera CEO Sven Van Den Berghe said in an interview with Fierce Pharma. “The next revolution is coming right after that, which is the actinium-225, and it requires a completely different production route, which is the space we are working in.”
Less than two months ago, Bristol Myers Squibb entered the radiopharma race with its $4.1 billion acquisition of RayzeBio, paying more than triple what the biotech secured during its IPO when it went public just three months previously. The draw for BMS was RayzeBio’s platform based on Ac-225.
“It’s more efficient to deBristol Myers Squibbl,” PanTera’s chief business officer, Christophe Malice, said in thRayzeBioiew.RayzeBio
In addition to being more destructivcancerhe cancer cell, as an alpha emitter, an Ac-225 therapy can be more fine-tuned to the target, PanTera says.
PanTera is in a “unique position” to be a leacancerupplier of Ac-225 in Europe, the company said in its release this week.
In June of last year, the company struck a supply deal with Bill Gates-founded TerraPower Isotopes, which extracts Ac-225 from legacy nuclear material in the U.S. PanTera will serve as TerraPower’s European partner.
While small-scale suppliers are starting to emerge and can take care of some of the demand for clinical trials, PanTera’s goal is to quickly scale up to meet the oncoming commercial demand.
“In the 2027-29 period, these drugs will really be coming out of the clinical trials and be launched on the market. That’s when we want our big-scale supply to be available,” Van Den Berghe said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.